Bayer holds a diversified product portfolio in more than one industry. Thus, it is not crippled by slumps in individual industries. In the pharmaceutical industry, known for its high risk associated with drug development and litigation costs, the company has no less than 15 products accounting for 66% of its pharma revenues, plenty of which are not in danger of losing their patents any time soon.